Sugi Predict

Sugi Predict / Compounds / SCHEMBL768353

SCHEMBL768353

SCHEMBL768353

N#CC1CCOc2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB2 P05107 1/20 0.41
▸ ICAM1 P05362 1/20 0.41
▸ ITGAL P20701 1/20 0.41
▸ DPP4 P27487 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ CRHBP P24387 2/20 0.38
▸ CRHR2 Q13324 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ MAP3K14 Q99558 1/20 0.35
▸ SSTR4 P31391 1/20 0.34
▸ TRPV1 Q8NER1 2/20 0.34
▸ HTR2A P28223 1/20 0.33
▸ ABCG2 Q9UNQ0 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ LTB4R Q15722 1/20 0.32
▸ LTB4R2 Q9NPC1 1/20 0.32
▸ OPRL1 P41146 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29959911 1.00 ITGB2 (0.41) ITGB2ICAM1ITGALDPP4LMNA
SCHEMBL29961242 0.89 ITGB2 (0.39) ITGB2ICAM1ITGALDPP4LMNA
SCHEMBL97553 0.81 ITGB2 (0.41) ITGB2ICAM1ITGALDPP4LMNA
SCHEMBL4524534 0.81 IMPDH2 (0.41) ITGB2ICAM1ITGALHTR2AABCG2
SCHEMBL26769086 0.77 ITGB2 (0.38) ITGB2ICAM1ITGALLMNACRHBP
SCHEMBL23704789 0.76 ADRA2A (0.47) LMNAHTTMAP3K14
SCHEMBL9432676 0.76 ADRA2A (0.38) LMNASMN1; SMN2TRPV1
SCHEMBL2776662 0.76 HSD17B2 (0.39) LMNAHTTMAP3K14TRPV1LRRK2
SCHEMBL7128481 0.76 CYP19A1 (0.44) ITGB2ICAM1ITGAL
SCHEMBL8083561 0.75 ITGB2 (0.46) ITGB2ICAM1ITGALLMNACRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270210-A1 BCL-2 Inhibitor BEIGENE, LTD. (KY) 2025-08-28 — — US disclosed
US-12286430-B2 Bcl-2 inhibitor BEIGENE, LTD. (KY) 2025-04-29 — — US disclosed
US-20240376097-A1 BCL-2 Inhibitor BEIGENE LTD. (KY) 2024-11-14 — — US disclosed
CN-118265700-A Substituted naphthyridinone derivative, pharmaceutical composition and application thereof 上海海雁医药科技有限公司 2024-06-28 — — CN disclosed
CN-116969937-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 — — CN disclosed
CN-116969936-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 — — CN disclosed
CN-116802179-A BCL-2 inhibitors 百济神州有限公司 2023-09-22 — — CN disclosed
US-20230159522-A1 BCL-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 — — US disclosed
WO-2023083210-A1 SUBSTITUTED NAPHTHYRIDINONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海海雁医药科技有限公司 2023-05-19 — — WO disclosed
WO-2023083210-A1 SUBSTITUTED NAPHTHYRIDINONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海海雁医药科技有限公司 2023-05-19 — — WO disclosed
CN-103450138-B Preparation of intermidiates of 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2015-04-08 — — CN disclosed
CN-103450138-A Preparation of intermidiates of 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2013-12-18 — — CN disclosed
CN-102131794-B 6-substituted phenoxy chroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2013-09-25 — — CN disclosed
CN-102603693-A Preparation process of ethyl chromane-4-formate SUZHOU LAKESTAR PHARMATECH CO LTD 2012-07-25 — — CN disclosed
US-20120071506-A1 METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES GALLEY GUIDO (DE) 2012-03-22 — — US disclosed
CN-102131794-A 6-substituted phenoxy chroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2011-07-20 — — CN disclosed
EP-1981499-A1 USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS F.HOFFMANN-LA ROCHE AG (CH) 2008-10-22 — — EP disclosed
US-20070197620-A1 Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles HOFFMANN-LA ROCHE INC. 2007-08-23 — — US disclosed
WO-2007085558-A1 USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 — — WO disclosed
US-4659737-A Substituted aminomethyl benzopyrans having anti-hypertensive activities BAYER AKTIENGESELLSCHAFT (DE) 1987-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071506-A1 METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES CRY1, PER2, GPR119 ITGB2 3882/4885ICAM1 2157/4885ITGAL 4077/4885
US-20250270210-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 ITGB2 3529/4885ICAM1 3053/4885ITGAL 4770/4885
US-20230159522-A1 BCL-2 INHIBITOR BCL2, BCL2A1, BCL2L1 ITGB2 3529/4885ICAM1 3053/4885ITGAL 4770/4885
US-20240376097-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 ITGB2 3529/4885ICAM1 3053/4885ITGAL 4770/4885
US-20070197620-A1 Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles CRY1, PER2, GPR119 ITGB2 3802/4885ICAM1 2003/4885ITGAL 3939/4885
US-12286430-B2 Bcl-2 inhibitor BCL2, BCL2A1, BCL2L1 ITGB2 3529/4885ICAM1 3053/4885ITGAL 4770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.